deltatrials
Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04797884

Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma (ARTEMIS)

A Randomized Study of Intrabucally Administered Electromagnetic Fields Versus Placebo for Patients With Child-Pugh A or B With Advanced Hepatocellular Carcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Hepatocellular Carcinoma
Interventions Placebo Device Quality of Life Assessment TheraBionic Device
Updated 20 times since 2021 Last updated: Jun 25, 2023 Started: Jul 31, 2023 Primary completion: Oct 30, 2024 Completion: Oct 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04797884, this PHASE2/PHASE3 trial focuses on Hepatocellular Carcinoma and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 20 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Apr 2022 · 4 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 14 months · monthly snapshot

Change History

20 versions recorded

  1. Jun 2025 — Present [monthly]

    Unknown PHASE2/PHASE3

    Status: Recruiting → Unknown

  2. Sep 2024 — Jun 2025 [monthly]

    Recruiting PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Recruiting PHASE2_PHASE3

    Phase: PHASE2 → PHASE2_PHASE3

  5. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

▶ Show 15 earlier versions

  1. Mar 2023 — May 2023 [monthly]

    Recruiting PHASE2

  2. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  3. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  5. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  6. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  7. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  8. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  9. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  10. Dec 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  11. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  12. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

  14. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE2

  15. Apr 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • THERABIONIC INC.
Data source: THERABIONIC INC.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations